Tag: VMT-𝛼-NET

Update 29th July 2026. Perspective Therapeutics received orphan medicinal product designation from the European Commission for [212Pb]VMT-α-NET, a treatment targeting gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This status offers development and commercial benefits, including potential market exclusivity for up to 10 years, reflecting the drug's promise to address unmet needs in GEP-NET patients. The drug is currently in Phase 1/2a trials showing encouraging interim results. The designation supports further development and potential approval in Europe, aiming to improve treatment options for patients with limited therapies.   Update 21 June 2025. Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort…